ultra.news Open in urlscan Pro
103.200.72.228  Public Scan

Form analysis
1 forms found in the DOM

POST https://feedburner.google.com/fb/a/mailverify

<form style="border: 1px solid #ccc; padding: 3px; text-align: center;" action="https://feedburner.google.com/fb/a/mailverify" method="post" target="popupwindow">Sign up to get the latest Pharma-related news delivered via email: <input
    style="width: 140px;" name="email" type="text">
  <input name="uri" type="hidden" value="ultrapharmanews"><input name="loc" type="hidden" value="en_US"><input type="submit" value="Subscribe">
  <p style="font-size: small;">Don't forget to click on the activation link we send to your email</p>
</form>

Text Content

Ultra News

Primary Menu
 * HOME
 * BUSINESS
   * AUTO
   * RETAIL
   * ENERGY
   * FINANCE
   * AVIATION
   * INFOTECH
   * EDUCATION
   * HOSPITALITY
   * HEALTHCARE
   * REAL ESTATE
   * COMMODITIES
   * ENTERTAINMENT
   * COMMUNICATION
   * MANUFACTURING
 * CONSUMER
   * APPS
   * CARS
   * BIKES
   * PHONES
   * TABLETS
   * INTERNET
   * COMPUTERS
   * ENTERTAINMENT
 * SOCIETY
   * LAW
   * ARTS
   * CRIME
   * SPORTS
   * SCIENCE
   * POLITICS
   * CELEBRITIES
   * ENVIRONMENT
 * SPECIALS
   * FIRST ON ULTRA
   * ONLY ON ULTRA
 * ABOUT US
   * ABOUT
   * LEGAL
   * FEEDS
   * CONTACT
   * AUTHORS/MEMBERS


BIOCON MALAYSIA INSULIN ASPART PLANT HIT WITH 6 OBSERVATIONS BY US FDA

2021-09-252021-09-25 | Sreejiraj Eluvangal

Six months after getting a VAI status from the US Food & Drug Administration for
its insulin glargine manufacturing facility in Malaysia, Biocon — India’s
largest biopharmaceuticals company — said the US FDA issued six observations
after pre-approval inspections at its insulin aspart plant in that country.

Insulin glargine is a long-acting insulin-substitute, while insulin aspart is a
fast-acting substitute. The two are often administered together for optimal
effect.

US FDA approval is a must if the company has to export insulin aspart to the US
market.

Biocon said the observations have been issued across drug substance, drug
product and devices facilities

“We are confident of addressing these observations through procedural
enhancements and an appropriate Corrective and Preventive Action Plan (CAPA),
which will be submitted to the US FDA in the stipulated time.

“We do not expect the outcome of this inspection to impact our commercialization
plans for insulin Aspart in the US. Biocon Biologics remains committed to global
standards of Quality and Compliance,” it added.

In February this year, the glargine plant in Biocon’s Malaysian facility was
given a ‘voluntary action indicated’ classification after three observations
were issued on inspection.

The FDA classifies each plant under three categories after each inspection – NAI
or no action indicated, VAI or voluntary action indicated and OAI or official
action indicated.

Voluntary Action Indicated (VAI) means the inspectors found objectionable
conditions or practices but the agency is not prepared to take or recommend any
administrative or regulatory action.

BUSINESS HEALTHCAREBIOCON USFDATWEETWHATSAPPFACEBOOK





RELATED

Lupin gets US FDA warning letter for Somerset plant Lupin Ltd, one of the
world's largest generic drug makers, today said it received a warning letter
from the US…
Glenmark, Cipla get US nod for inhaler drug Indian pharmaceutical manufacturers
Cipla and Glenmark Pharma said they received approval from the US Food and Drug
Administration to launch…
Alkem's Taloja test facility passes US FDA inspection Pharmaceuticals
manufacturer Alkem Laboratories said its bioequivalence center at Taloja in
Maharashtra has successfully undergone a US FDA inspection without…
Zydus Cadila signs deal with Shipa Medicare for ZyCoV-D production Cadila
Healthcare, also known as Zydus Cadila, has taken one more step towards
augmenting the production capacity for its DNA-based…
Lupin gets license to manufacture new TB drug Indian pharmaceuticals
manufacturer Lupin Ltd said it received a non-exclusive license to manufacture
the anti-TB drug pretomanid from non-profit drug…
Zydus Cadila gets US-FDA nod for antidepressant drug It is a relatively new
antidepressant sold by Takeda Zydus Cadila said it received approval from the US
Food &…
Cadila Healthcare hopes to get Zydus COVID vaccine approval in 1-2 weeks Cadila
Healthcare MD Sharvil Patel said the company has started stockpiling the ZyCoV-D
COVID vaccine, and is in the process…
Zydus Cadila gets 6-month exclusivity in US for arthritis drug Zydus Cadila said
it received six-month exclusivity for the sale of generic tofacitinib, a drug
that has annual sales of…
Dr Reddy's launches 2DG Covid drug for Rs 990 Dr Reddy's Laboratories, one of
India's largest pharmaceutical manufacturers, commercially launched 2DG COVID-19
treatment today, starting with the bigger cities.…
Zydus Cadila launches blood thinner in the US Cadila Healthcare said it has
launched a generic blood thinning medication, Enoxaparin Sodium Injection, in
the US, where the drug…
Natco Pharma starts Ph III trial of new COVID drug molnupiravir The drug was
developed at Emory University Less than a month after it approved for clinical
trial approval, Hyderabad-based Natco…
AstraZeneca annuls diabetes drug deal with Abbott Healthcare AstraZeneca India,
which entered into a licensing deal with Sun Pharma for a key diabetes drug,
said that it had…
Yes Bank says Dish TV resorting to 'dilatory tactics', seeks EGM Yes Bank, which
holds around 26% of Dish TV India, accused the direct-to-home satellite provider
of resorting to what it…
AstraZeneca rejigs diabetes drug deal with Sun Pharma AstraZeneca Pharma India,
the local unit of the global pharmaceuticals giant, said it has decided to end
its marketing agreement…
Zydus Cadila launches affordable breast cancer drug in India Zydus Cadila, the
pharmaceutical arm of the Zydus group, said it has launched a next-generation
breast cancer drug in India…
Gufic Lifesciences gets nod for injectables unit merger Gufic Lifesciences Ltd,
one of the oldest pharma companies in India, today said it has won the last
pending regulatory…
Tata Power wins mega solar power contract from Maharashtra Tata Power said it
signed a preliminary agreement to set up and supply power from a 250 megawatt
solar power…
Dish TV seeks to postpone AGM, says directors can't be removed without nod Dish
TV India, one of the largest direct-to-home satellite broadcasters in the world,
said a shareholder resolution calling for the…

Sign up to get the latest Pharma-related news delivered via email:

Don't forget to click on the activation link we send to your email

ULTRA CORPORATE NEWS